Dr Abdul Mannan: CVT Risk With CHC is Not One-Size-Fits-All
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“CVT risk with CHC is not one-size-fits-all. The type of progestin matters enormously (fourth-generation worst), and the multiplication of risk factors (family history, thrombophilia, obesity) creates scenarios with 200+ fold increased risk.
Most important clinical change:
Take family history more seriously – it predicts risk independently of thrombophilia testing. And if you’re prescribing CHC, think twice about fourth-generation progestins.
The absolute risk remains low for most women, but for that high-risk subset (family history + thrombophilia), the numbers are sobering enough to have serious conversations about alternative contraception.”
Title: The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
Authors: Maria Abbattista, Addolorata Truma, Ida Martinelli, Francesca Gianniello, Serena M. Passamonti, Marco Capecchi, Andrea Artoni, Flora Peyvandi, Paolo Bucciarelli
Read full article here.
Stay updated with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy